A Phase 1 interventional study of Trazodone and Quetiapine in Healthy, sponsored by University of Ottawa. Status unknown at 1 site in Canada. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-07-22.
Sponsored by University of Ottawa · Phase 1, Interventional, and Treatment
Generic describes a pharmaceutical product that does not have a brand name or trademark. Generic medications should be the equivalent of brand medications. Only their price should be different. The active ingredient of the generic medication has to be within a window of 80 to 125% of the original in the blood. There are reports that this standard is not always followed after the medication has been on the market. Indeed, it was observed that some patients previously stable on original medications relapsed when switched to a generic. Several factors could account for this problem. Such problems have been reported for Pindolol, Quetiapine, and Trazodone. Some properties of specific brands of the generics and the original brands will be examined for these three medications. The three original medications used in this study are the Visken, the Seroquel, and the Desyrel. The three generics are the Teva-pindolol, the Teva-Quetiapine, and the Teva-Trazodone. They are all available on the Canadian market by prescription.
University of Ottawa is the lead sponsor of 123 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Both drugs will be given at the dose of 150 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication.
Drug: Trazodone · Procedure: Blood Collection
Both drugs will be given at the dose of 10 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
Drug: Pindolol · Procedure: Blood Collection
Both drugs will be given at the dose of 100 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
Drug: Quetiapine · Procedure: Blood Collection
each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
Also known as: Desyrel, Teva-Trazodone
each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
Also known as: Seroquel, Teva-Quetiapine
each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
Also known as: Visken, Teva-Pindolol
Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
Plasma levels of Medication
Time frame: 0 to 48 hours after drug ingestion
This study is status unknown, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Ottawa